Laurus Labs Q2 FY27: record revenue, higher margin and expansion plans

Order pipeline disclosedMulti-year targets disclosedInvestor Communications View source PDF Explain this filing

LAURUSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.7%Reaction day

₹2348.00

prior close

₹2257.70

announcement price

In-mkt

timing

Nifty Midcap 150market+1.0%-2.7% vs market

Pharmaceuticals peers, median of 170sector+0.1%-1.8% vs sector

On the reaction day the stock moved 2.7 pts less than Nifty Midcap 150 and 1.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.1

15m

-0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.7+1.0-2.7+0.1-1.8

Next day

-1.6+2.6-4.2+1.1-2.8

-0.4+4.6-5.0+2.0-2.4

-0.3pendingpending+1.9-2.2

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 revenue hit a record INR2,206 crore, with 63% gross margin, INR762 crore EBITDA at 34.5% and INR441 crore profit after tax. CDMO sales rose 86% to INR875 crore; affordable medicines grew 15% to INR1,302 crore. H1 revenue was INR4,233 crore. Net debt was INR2,466 crore; debt to EBITDA was 1.02 times. Management retained over 60% gross margin and over 30% EBITDA guidance for FY27 and plans INR3,000 crore capex across FY27-FY28.

Likely market impact

Strong growth and lower leverage support the stock, though expansion spending and delayed peptide revenues may limit near-term cash flow.